Methods for Treating Cancer That Has A Phosphatidylinositol 3,4,5-Trisphosphate Rac Exchange Factor 2 (PREX2) Protein Expressed Thereon
AssigneeKaohsiung Medical University
InventorYi-Ming Chen
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of treating a cancer in a subject having or suspected of having the cancer that has a mutated PREX2 expressed thereon. According to the embodiment of the present disclosure, the mutation is G258V, S1113R, E1346D or K400fs. The method includes the step of administering an effective amount of a composition to the subject, wherein the composition includes a therapeutic molecule for producing a polypeptide that exhibits a binding affinity to the mutated PREX2 protein expressed in the cancer in the subject.
Claims9
A method of treating a cancer in a subject having or suspected of having the cancer that has a phosphatidylinositol 3,4,5-trisphosphate Rac exchange factor 2 (PREX2) protein expressed thereon, wherein the expressed PREX2 protein is a mutated PREX2 protein comprising at least one mutation selected from the group consisting of G258V, S1113R, E1346D and K400fs when compared to SEQ ID NO:
- 7, the method comprising:
- administering an effective amount of a composition to the subject having or suspected of having the cancer that has the PREX2 protein expressed thereon, wherein the composition comprises a therapeutic molecule for producing a polypeptide that exhibits a binding affinity to the mutated PREX2 protein expressed in the cancer in the subject.
Dependencies are inferred from the claim text.